Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a …
Background Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer.
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …
Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial
SL Topalian, S Bhatia, A Amin… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven
by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed …
by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed …
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D'Angelo, J Russell, C Lebbé, B Chmielowski… - JAMA …, 2018 - jamanetwork.com
Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
[HTML][HTML] Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical …
HL Kaufman, JS Russell, O Hamid, S Bhatia… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
[HTML][HTML] First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II …
Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …